Quick Overview of Apellis Pharmaceuticals

By Tamara Parker • Tuesday, March 28 07:57 • Permanent Link

Shares of Pharmaceutical company Apellis Pharmaceuticals jumped 4.17% today. With many investors piling into APLS without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Apellis Pharmaceuticals has moved 34.8% over the last year, and the S&P 500 logged a change of -14.12%
APLS has an average analyst rating of buy and is -23.05% away from its mean target price of $85.33 per share
Its trailing earnings per share (EPS) is $-6.15
Apellis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -10.68 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-3.45 and its forward P/E ratio is -19.03
The company has a Price to Book (P/B) ratio of 17.67 in contrast to the S&P 500's average ratio of 2.95
Apellis Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.